Irish Smokers with Rheumatoid Arthritis Suffer More Than Their Nonsmoking Counterparts

LEONARD C. HARTY and DOUGLAS J. VEALE

J Rheumatol 2010;37;1062
http://www.jrheum.org/content/37/5/1062

1. Sign up for TOCs and other alerts
   http://www.jrheum.org/alerts

2. Information on Subscriptions
   http://jrheum.com/faq

3. Information on permissions/orders of reprints
   http://jrheum.com/reprints_permissions

*The Journal of Rheumatology* is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
Irish Smokers with Rheumatoid Arthritis Suffer More Than Their Nonsmoking Counterparts

To the Editor:

We have noted a 1.5 relative risk (RR) of people with inflammatory arthritis failing at least one anti-tumor necrosis factor (TNF) therapy and a 1.6 RR of failing disease-modifying antirheumatic drug (DMARD) therapy if they are "ever-smokers" (current or past smokers). This is based on a prospective longitudinal analysis of 793 patients, of whom 102 (13%) were deemed to have failed an anti-TNF drug due to inefficacy and 452 patients who previously failed a conventional DMARD for whom smoking data were available. Sixty percent of the database cohort were ever-smokers whereas the remaining 40% never smoked tobacco. It has recently been proposed1 that exposure to tobacco smoke reduced the efficacy of anti-TNF therapy in patients with rheumatoid arthritis (RA). Mattey, et al noted higher Disease Activity Scores (DAS) in ever-smokers compared with never-smokers despite the use of anti-TNF therapy, and therefore inferred that tobacco smoking, current or past, impairs the therapeutic action of these advanced biologic agents. They found that the higher DAS scores among ever-smokers were due to patient global scores on visual analog scales (VAS) and tender joint counts, yet found no differences in levels of inflammatory markers, swollen joint counts, and physician global VAS between ever- and never-smokers. These findings suggest a greater incidence of periarticular pain syndromes among RA ever-smokers than RA never-smokers, rather than proving a greater incidence of active synovitis despite anti-TNF therapy in the ever-smoking RA group. However, reflecting upon our own database findings, ever-smokers had a marginally higher mean swollen joint count than never-smokers at both 3 and 12 months while also having higher tender joint counts and overall DAS scores (Table 1).

Ever-smoking patients with fibromyalgia suffer more pain than never-smoking patients with fibromyalgia. A large robust population-based German study with almost 7000 participants showed that people who smoked had a 3.1-fold RR (95% CI 1.8–5.3) of using analgesics daily, indicating a lower pain threshold among ever-smokers compared to never-smokers2. The mechanism of this enhanced nociception is unclear and is the subject of much speculation. Tobacco smoke is composed of an estimated 4000 chemical constituents. It would follow that at least one of these compounds results in greater nociception. Of these, about 400 have been measured or estimated in mainstream and sidestream smoke. Of the 400, significant toxicology data exist for fewer than 100. It will therefore be challenging to discover which of the compounds of inhaled tobacco smoke may exert this noxious effect. Nicotine, tar, and carbon monoxide are among the 3 better-known inhaled by-products of tobacco smoke. Of these, nicotine is known to have an analgesic effect via stimulation of both peripheral and central nicotinic receptors3 and has been shown to attenuate the onset of collagen-induced arthritis in rodents4, yet considering the current objective evidence of inflammation? Is a noninflammatory immune reaction responsible for the enhanced pain perception of people who smoke? The Journal of Rheumatology 2010;37:5; doi:10.3899/jrheum.091403

REFERENCES


Table 1. Smoking status compared to disease activity scores (DAS) and tender joint counts (TJC) and swollen joint counts (SJC) after 3 and 12 months of anti-TNF therapy.

<table>
<thead>
<tr>
<th>Smoking Status</th>
<th>At 3 Months</th>
<th></th>
<th></th>
<th>At 12 Months</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DAS</td>
<td>TJC</td>
<td>SJC</td>
<td>DAS</td>
<td>TJC</td>
<td>SJC</td>
</tr>
<tr>
<td>Current smokers</td>
<td>3.42</td>
<td>3.96</td>
<td>4.27</td>
<td>3.04</td>
<td>3.40</td>
<td>2.97</td>
</tr>
<tr>
<td>Ex-smokers</td>
<td>3.26</td>
<td>3.37</td>
<td>3.51</td>
<td>3.09</td>
<td>3.28</td>
<td>2.62</td>
</tr>
<tr>
<td>Never-smokers</td>
<td>3.26</td>
<td>3.12</td>
<td>3.55</td>
<td>2.8</td>
<td>2.39</td>
<td>2</td>
</tr>
</tbody>
</table>